Zobrazeno 1 - 10
of 9 248
pro vyhledávání: '"John A"'
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Karen A. Maegley, Kephart Susan Elizabeth, Christopher P. Dillon, Manli Shi, Kristen Jensen-Pergakes, Prakash B. Palde, Ya-Li Deng, Chi-Yeh Chung, Natalie Miller, John Sherrill, Wei Liu, Ryan L. Patman, Shinji Yamazaki, Tao Xie, Fen Wang, Hieu Lam, Eleanore Hendrickson, John F. Braganza, Yuli Wang, Robert Arnold Kumpf, Shannon Karlicek Bryant, Thomas A Paul, Noah Spiegel, Martin James Wythes, Amy Nemeth, Stephanie Scales, Elizabeth A. McMillan, Michelle Tran-Dubé, Alexei Brooun, Vesta Goshtasbi, Eugene Rui, Michele McTigue, Indrawan James Mcalpine, Tatlock John H
Publikováno v:
Molecular Cancer Therapeutics. 21:3-15
Protein arginine methyltransferase 5 (PRMT5) overexpression in hematologic and solid tumors methylates arginine residues on cellular proteins involved in important cancer functions including cell-cycle regulation, mRNA splicing, cell differentiation,
Autor:
Meghan C. Thompson, Andre Goy, Chan Yoon Cheah, Matthew S. Davids, Neil E. Kay, Chadi Nabhan, Constantine S. Tam, Mazyar Shadman, Anthony R. Mato, Kerry A. Rogers, Lindsey E. Roeker, Arnon P. Kater, John F. Seymour, John M. Pagel, Joanna Rhodes, Clare Sun, Alan P Skarbnik, Catherine C. Coombs, Toby A. Eyre, Jennifer R. Brown, Jennifer A. Woyach, Chaitra Ujjani, Stephen J. Schuster, Susan O'Brien, Danielle M. Brander, Nicole Lamanna, Nitin Jain, Jeff P. Sharman
Publikováno v:
Clin Cancer Res
Clinical Cancer Research, 28(4), 603-608. American Association for Cancer Research Inc.
Clinical cancer research, 28(4), 603-608. American Association for Cancer Research Inc.
Mato, A R, Davids, M S, Sharman, J, Roeker, L E, Kay, N, Kater, A P, Rogers, K, Thompson, M C, Rhodes, J, Goy, A, Skarbnik, A, Schuster, S J, Tam, C S, Eyre, T A, O'Brien, S, Nabhan, C, Lamanna, N, Sun, C, Shadman, M, Pagel, J M, Ujjani, C, Brander, D, Coombs, C C, Jain, N, Cheah, C Y, Brown, J R, Seymour, J F & Woyach, J A 2022, ' Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL : “What's Past Is Prologue” (Shakespeare) ', Clinical Cancer Research, vol. 28, no. 4, pp. 603-608 . https://doi.org/10.1158/1078-0432.CCR-21-1237
Clinical Cancer Research, 28(4), 603-608. American Association for Cancer Research Inc.
Clinical cancer research, 28(4), 603-608. American Association for Cancer Research Inc.
Mato, A R, Davids, M S, Sharman, J, Roeker, L E, Kay, N, Kater, A P, Rogers, K, Thompson, M C, Rhodes, J, Goy, A, Skarbnik, A, Schuster, S J, Tam, C S, Eyre, T A, O'Brien, S, Nabhan, C, Lamanna, N, Sun, C, Shadman, M, Pagel, J M, Ujjani, C, Brander, D, Coombs, C C, Jain, N, Cheah, C Y, Brown, J R, Seymour, J F & Woyach, J A 2022, ' Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL : “What's Past Is Prologue” (Shakespeare) ', Clinical Cancer Research, vol. 28, no. 4, pp. 603-608 . https://doi.org/10.1158/1078-0432.CCR-21-1237
The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance
Autor:
Shi Ming Tu, Sumit K. Subudhi, Ana Aparicio, Ioannis Alafis, Brian F. Chapin, Xuemei Wang, Myrto Boukovala, Paul G. Corn, Nicholas Spetsieris, John C. Araujo, Justin A. Weldon, Eleni Efstathiou, Jennifer Wang, Lisa Pruitt, Christopher J. Logothetis, Amado J. Zurita, John Papadopoulos, John J. Davis
Publikováno v:
European Journal of Cancer. 157:259-267
Background Intermittent androgen deprivation therapy (ADT) in biochemically recurrent castration-naive prostate cancer is non-inferior to continuous therapy. We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to A
Autor:
Ana Galan-Cobo, John V. Heymach, Uma Giri, Mary Ayres, William G. Wierda, John D. Minna, Monique B. Nilsson, Jing Wang, Yu Qian, Ferdinandos Skoulidis, Pan Tong, Emrullah Yilmaz, Chao Yang, Ishita Akhter, Lixia Diao, Jayanthi Gudikote, Christine M. Stellrecht, Jie Ding, Varsha Gandhi, Xiao Qu, Youhong Fan
Publikováno v:
Mol Cancer Res
Loss-of-function somatic mutations of STK11, a tumor suppressor gene encoding LKB1 that contributes to the altered metabolic phenotype of cancer cells, is the second most common event in lung adenocarcinomas and often co-occurs with activating KRAS m
Autor:
Ruth E Langley, David P. Dearnaley, H. Rush, Silke Gillessen, Mahesh K. B. Parmar, Andrew Protheroe, Robin Millman, Shaun Tolan, Zaf Malik, Peter Hoskin, Christopher D. Brawley, Duncan C. Gilbert, Simon Chowdhury, Noel W. Clarke, Sarah Rudman, Nicholas D. James, Carla Perna, Neil McPhail, J. Martin Russell, Robert Jones, John Wagstaff, Adrian Cook, Gerhardt Attard, Joanna Gale, Salil Vengalil, Emma Gray, Alison Birtle, David Gareth Fackrell, Jacob Tanguay, Matthew R. Sydes, Archie Macnair, Joe M. O'Sullivan, Chris Parker, Alicia K. Morgans, Laura Murphy, David Matheson, C. Pugh
Publikováno v:
J Clin Oncol
PURPOSE Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Th
Autor:
Melissa Papargiris, Natalie Lister, Hong Wang, Renea A. Taylor, Sam Norden, Shivakumar Keerthikumar, Andrew Ryan, Mahesh Iddawala, Michelle Richards, David L Goode, Mitchell G. Lawrence, Shomik Sengupta, Andrew Bakshi, Shahneen Sandhu, Jeremy Grummet, Laurence Harewood, John F. Ouyang, David Clouston, Heather Thorne, Luc Furic, Jeremy Goad, Rosalia Quezada Urban, Birunthi Niranjan, Nicholas Choo, Ashlee K. Clark, Carmel Pezaro, Samantha O'Dea, Daniel Moon, Declan G. Murphy, Lisa Devereux, Gail P. Risbridger, Jenna Kraska, Laura H Porter, Mark Frydenberg, Linda Teng, Rodney J. Hicks, Zhuoer Li, Heather B Madsen, David Pook, William Wheelahan, Arun Azad, John Pedersen, Roxanne Toivanen, John Kourambas, Edmond M. Kwan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications
Nature Communications
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collecti
Autor:
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, David Hugo Flores, Agustin Falco, Matias Molina, Filip Van Aelst, Brieuc Sautois, Jean-Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sergio J Azevedo, Gisele Marinho, Joao Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, Andre Poisl Fay, Joel Gingerich, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, Jose Luis Leal, Francisco Francisco, Carolina Ibanez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Flechon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross-Goupil, Stephane Culine, Gwenaelle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David Pfister, Carsten Ohlman, Michael Stoeckle, Manfred Wirth, Anja Lorch, Guenter Niegisch, Peter J Goebell, Martin Boegemann, Axel Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian Thomas, Thomas Hoefner, Andras Telekes, Judit Erzsebet Kosa, Janos Revesz, Gyorgy Bodoky, Tibor Csoszi, Andras Csejtei, Lajos Geczi, Agnes Ruzsa, Zsuzsanna Kolonics, Jozsef Erfan, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger, Keren Rouvinov, David Sarid, Satoshi Fukasawa, Gaku Arai, Akito Yamaguchi, Akira Yokomizo, Tatsuya Takayama, Hidefumi Kinoshita, Eiji Kikuchi, Ryuichi Mizuno, Yasuhisa Fujii, Naoto Sassa, Yoshihisa Matsukawa, Kiyohide Fujimoto, Toshiki Tanikawa, Yoshihiko Tomita, Kazuo Nishimura, Masao Tsujihata, Masafumi Oyama, Naoya Masumori, Hiroomi Kanayama, Toshimi Takano, Yuji Miura, Jun Miyazaki, Akira Joraku, Tomokazu Kimura, Yoshiaki Yamamoto, Kazuki Kobayashi, Ronald De Wit, Maureen Aarts, Winald Gerritsen, Maartje Los, Laurens Beerepoot, Adel Izmailov, Sergey Igorevich Gorelov, Boris Yakovlevich Alekseev, Andrey Semenov, Vladimir Anatolyevich Kostorov, Sergey M Alekseev, Alexander Zyryanov, Vasiliy Nikolaevich Oschepkov, Vladimir Aleksandrovich Shidin, Vladimir Ivanovich Vladimirov, Rustem Airatovich Gafanov, Petr Alexandrovich Karlov, David Brian Anderson, Lucinda Shepherd, Graham Lawrence Cohen, Bernardo Louis Rapoport, Paul Ruff, Nari Lee, Woo Kyun Bae, Hyo Jin Lee, Urbano Anido Herranz, Enrique Grande, Teresa Alonso Gordoa, Josep Guma Padro, Daniel Castellano Gauna, Jose Angel Arranz, Jose Munoz Langa, Regina Girones Sarrio, Alvaro Montesa Pino, Maria Jose Juan Fita, Yu-Li Su, Yung-Chang Lin, Wen-Pin Su, Ying-Chun Shen, Yen-Hwa Chang, Yi-Hsiu Huang, Virote Sriuranpong, Phichai Chansriwong, Vichien Srimuninnimit, Pongwut Danchaivijitr, Huseyin Abali, Sinan Yavuz, Ozgur Ozyilkan, Mehmet Ali Nahit Sendur, Meltem Ekenel, Mustafa Ozguroglu, Cagatay Arslan, Mustafa Ozdogan, Alison Birtle, Robert Huddart, Maria de Santis, Anjali Zarkar, Linda Evans, Syed Hussain, Christopher DiSimone, Antonio F Muina, Peter Schlegel, Haresh S Jhangiani, Michael Harrison, Dennis E Slater, David Wright, Ivor J Percent, Jianqing Lin, Clara Hwang, Sumati Gupta, Madhuri Bajaj, Robert Galamaga, John Eklund, James Wallace, Mikhail Shtivelband, Jason Jung-Gon Suh, Nafisa Burhani, Matthew Eadens, Krishna Gunturu, Earle Burgess, John Wong, Arvind Chaudhry, Peter Van Veldhuizen, Stephanie Graff, Christian A Thomas, Ian D Schnadig, Benedito Carneiro, Maha Hussain, Alicia Morgans, John T Fitzharris, Ira A Oliff, Jacqueline Vuky, Ralph Hauke, Ari Baron, Monika Joshi, Britt H Bolemon, Peter Jiang, Anthony E Mega, Maurice Markus, Nicklas Pfanzelter, William Eyre Lawler, Patrick Wayne Cobb, Jay G Courtright, Sharad Jain, Gurjyot Doshi, Vijay K Gunuganti, Oliver Alton Sartor, Scott W Cole, Hani Babiker, Edward M Uchio, Alexandra Drakaki, Heather D Mannuel, Elizabeth Guancial, Chunkit Fung, Anthony Charles, Robert J Amato, Yull Arriaga, Isaac Bowman, Steven Ades, Robert Dreicer, Evan Yu, David I Quinn, Mark Fleming
Publikováno v:
The lancet oncology
The Lancet. Oncology, Vol. 22, no. 7, p. 931-945 (2021)
The Lancet. Oncology, Vol. 22, no. 7, p. 931-945 (2021)
Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alon
Autor:
Matthew S. Davids, Ahmed Salem, Abhijeet Kumar, Andrew W. Roberts, William G. Wierda, John F. Seymour, Su Y. Kim, Michelle Boyer, Jennifer Arzt, Vaishalee P. Kenkre, Margaret Mantas, Thomas J. Kipps, John Pesko
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 17
Purpose: We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non–Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lympho
Autor:
Su Young Kim, Ruby Nandam, Brenda Chyla, Shuo Ma, John Pesko, John F. Seymour, Ahmed Salem, Amanda Jacobson, Michael Y. Choi, Thomas J. Kipps, Andrew W. Roberts, Abdullah A. Masud, Mary Ann Anderson, Jennifer Arzt, Danielle M. Brander, Kathryn Humphrey
Publikováno v:
Blood
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (2